Success Metrics

Clinical Success Rate
86.0%

Based on 178 completed trials

Completion Rate
86%(178/207)
Active Trials
1(0%)
Results Posted
53%(94 trials)
Terminated
29(12%)

Phase Distribution

Ph not_applicable
25
10%
Ph phase_1
15
6%
Ph early_phase_1
1
0%
Ph phase_2
24
10%
Ph phase_3
73
30%
Ph phase_4
94
39%

Phase Distribution

16

Early Stage

24

Mid Stage

167

Late Stage

Phase Distribution232 total trials
Early Phase 1First-in-human
1(0.4%)
Phase 1Safety & dosage
15(6.5%)
Phase 2Efficacy & side effects
24(10.3%)
Phase 3Large-scale testing
73(31.5%)
Phase 4Post-market surveillance
94(40.5%)
N/ANon-phased studies
25(10.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.4%

178 of 216 finished

Non-Completion Rate

17.6%

38 ended early

Currently Active

1

trials recruiting

Total Trials

242

all time

Status Distribution
Active(4)
Completed(178)
Terminated(38)
Other(22)

Detailed Status

Completed178
Terminated29
unknown22
Withdrawn9
Not yet recruiting3
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
242
Active
1
Success Rate
86.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (0.4%)
Phase 115 (6.5%)
Phase 224 (10.3%)
Phase 373 (31.5%)
Phase 494 (40.5%)
N/A25 (10.8%)

Trials by Status

completed17874%
withdrawn94%
recruiting10%
terminated2912%
not_yet_recruiting31%
unknown229%

Recent Activity

Clinical Trials (242)

Showing 20 of 242 trialsScroll for more
NCT03485417Phase 2

Substance Misuse To Psychosis for Stimulants

Completed
NCT05814640Phase 1

Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)

Recruiting
NCT06236451Phase 4

Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With Schizophrenia

Completed
NCT05545891Phase 2

Aripiprazole in Body Focused Repetitive Behaviors

Not Yet Recruiting
NCT02634463Phase 1

Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone

Completed
NCT01490086Phase 2

RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder

Completed
NCT07011693Phase 4

Switching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression(SMART-I)

Not Yet Recruiting
NCT06969755Phase 4

Biomarkers to Enhance Early Schizophrenia Treatment

Not Yet Recruiting
NCT02431702Phase 3

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

Completed
NCT03874494Phase 3

Safety and Efficacy of Brexpiprazole in the Treatment of Schizophrenia

Completed
NCT01119014Phase 4

Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis

Completed
NCT05322031Phase 4

The Impact of Aripiprazole Long-acting on Myelin and Cognition in the Onset of Schizophrenia

Completed
NCT03557931Phase 2

A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

Completed
NCT02918370Phase 3

Aripiprazole for Bipolar Disorder and Alcohol Use Disorder

Completed
NCT01617460Phase 3

A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder

Completed
NCT03522168

Long-term Antipsychotic Pediatric Safety Trial

Completed
NCT02893371

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated
NCT05554627Phase 4

VA Aripiprazole vs Esketamine for Treatment Resistant Depression

Withdrawn
NCT03198078Phase 3

Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia

Completed
NCT04030143Phase 1

A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder

Completed

Drug Details

Intervention Type
DRUG
Total Trials
242